NSEAnalysts/Institutional Investor Meet/Con. Call Updates5 Aug 2026 · 5 Aug 2026, 07:05 pm

Analysts/Institutional Investor Meet/Con. Call Updates

Akums Drugs and Pharmaceuticals Limited · AKUMS

✦ AI SummaryResults

Akums Drugs and Pharmaceuticals Limited has informed the Exchange about the schedule of an investor/analysts conference call for Q1 FY 27 un-audited financial results.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet

Attachments (1)

📄

NSEAKUMS10_05082026190449_AKUMSEARNINGCALLINTIMATION.pdf

pdf

Download →
View document text
Ref: Akums/Exchange/2026-27/36 August 05, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd BSE Limited Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring, Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy Bandra (E), Mumbai – 400 051 Towers, Dalal Street, Mumbai – 400 001 Symbol: AKUMS Scrip Code: 544222 Sub: Intimation of Schedule of the Investors/Analysts Conference Call (group meet) for un- audited financial results of Q1 FY 27 Respected Sir/Ma’am, This is to inform you that pursuant to regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Akums Drugs and Pharmaceuticals Limited will be hosting below scheduled investor/analysts conference call (group meet): S. No. Particulars of Date of Meeting Type of Location / Mode Meet Meet of Meeting 1 Earning/Quarterly 10th August, 2026 Group meet Virtual Calls Starts at 12:00 PM (IST) Please find enclosed Dial-in details for the same. Further, no unpublished price sensitive information pertaining to the Company will be shared during the meet with Analysts/Investors. Please note that the above may subject to change due to exigencies on the part of Investors/analysts or Company. A copy of this disclosure is being updated on website of the Company at www.akums.in This is for your information and records. For Akums Drugs and Pharmaceuticals Limited Dharamvir Malik Company Secretary & Compliance Officer Encl: As above Q1FY27 Earnings Call Akums Drugs & Pharmaceuticals August 10, 2026 at 12:00 pm (IST) Ambit Capital cordially invites you to the Q1FY27 Earnings Call of Akums Drugs & Pharmaceuticals Company Representatives Mr. Sanjeev Jain – Managing Director Mr. Sandeep Jain – Managing Director Mr. Sumeet Sood – Chief Financial Officer Mr. Sahil Maheshwari – Head Strategy The teleconference will be moderated by Umesh Laddha, Institutional Equities, Ambit Capital. Conference Call Details Date: August 10, 2026 | Time: 12:00 pm (IST) Please join the conference via Diamond Pass to avoid wait time. Please click here to register. +91 22 6280 1148 Primary Access Numbers +91 22 7115 8049 Singapore: 800 101 2045 Hong Kong: 800 964 448 International Toll Free Numbers USA: 1 866 746 2133 UK: 0 808 101 1573 We request you to dial in a few minutes prior to the scheduled time.